SAN DIEGO, Nov. 13, 2019 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the Company will participate as a gold sponsor at the Cervical Spine Research Society (CSRS) 47th Annual Meeting, November 21-23, 2019 at the New York Marriott Marquis in New York City.
"NuVasive's involvement at CSRS showcases our commitment to invest in and deliver cervical solutions to surgeons and patients," said Matt Link, president of NuVasive. "We look forward to displaying our cervical portfolio and previewing our new anterior cervical plate that has improved features to treat degeneration, trauma and deformity cases at this important meeting."
NuVasive's booth #307 will display its Advanced Materials Science™ cervical portfolio, which includes proprietary surface and structural technologies to enhance the osseointegration and biomechanical properties of surgical materials. This includes Cohere® cervical, a Porous PEEK™ interbody implant and Modulus® cervical, a fully porous titanium interbody implant. In addition, the Company will preview its anterior cervical plate at a surgeon event.
The Company will also host a lunch workshop Cervical Spine Surgery: Why Should I Change? Featuring Advanced Materials Science presented by Dr. Charles H. Crawford III, an orthopedic spine surgeon at Norton Leatherman Spine Center and Dr. J. Kenneth Burkus, an orthopedic spine surgeon at Hughston Clinic, on Thursday, November 21 from 11:30 a.m. – 1:30 p.m. EST in the Majestic Room of the New York Marriott Marquis.
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company's portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With more than $1 billion in revenues, NuVasive has approximately 2,600 employees and operates in more than 50 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products (including the iGA® platform), the Company's ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
SOURCE NuVasive, Inc.